AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and Equipment
CystadenocarcinomaCystadenocarcinoma, MucinousCystadenomaCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousCystadenoma, MucinousAppendiceal NeoplasmsMucoceleCystsPyonephrosisMixed Tumor, MesodermalOvarian NeoplasmsBiliary Tract NeoplasmsCystadenoma, PapillaryParotid NeoplasmsBarium SulfatePseudomyxoma PeritoneiBile Ducts, IntrahepaticBile Duct NeoplasmsRetroperitoneal NeoplasmsPancreatic NeoplasmsTomography, X-Ray ComputedSalivary Gland NeoplasmsPancreatectomyHydroxy AcidsPancreaticoduodenectomy

Prognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovary. (57/83)

 (+info)

A case of intratesticular endometrioid papillary cystadenocarcinoma. (58/83)

 (+info)

Expression of alphaV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-alphaV-integrin antibody. (59/83)

 (+info)

Urachal papillary cystadenocarcinoma: a rare case report. (60/83)

 (+info)

Collision of three histologically distinct endometrial cancers of the uterus. (61/83)

 (+info)

The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer. (62/83)

 (+info)

Decreased expression of 14-3-3sigma is predictive of poor prognosis for patients with human uterine papillary serous carcinoma. (63/83)

Uterine papillary serous carcinoma (UPSC) morphologically resembles ovarian serous carcinoma and is categorized as a type II endometrial cancer. UPSC comprises about 10% of all types of endometrial cancer and has an aggressive clinical course and a poor prognosis. The 14-3-3sigma gene was originally discovered as a p53-inducible gene; its expression is induced by DNA damage in a p53-dependent manner, which leads to G2 arrest and repair of damaged DNA. Moreover, it has been reported that expression of 14-3-3sigma is frequently lost in various types of human cancer, including ovarian cancer. We therefore examined the association between 14-3-3sigma expression determined by immunohistochemistry and clinical outcomes of 51 patients with UPSC. UPSC was considered positive for 14-3-3sigma when > 30% of tumor cells were stained with a specific antibody. Of these patients, 29 (58.7%) showed positive immunoreactivity for 14-3-3sigma and 22 (41.3%) had decreased 14-3-3sigma staining. Decreased immunoreactivity for 14-3-3sigma was associated with stage (P = 0.001) and lymphovascular space involvement (P = 0.005). Moreover, decreased 14-3-3sigma expression was an independent risk factor for reduced overall survival (P = 0.0416) in multivariate analysis. Direct bisulfite sequencing was performed to evaluate the methylation status of the 27 CpG islands in the promoter region and first exon of the 14-3-3sigma gene. These CpG islands were hypermethylated in 30% of 14-3-3sigma-positive UPSC and 80% of 14-3-3sigma-negative UPSC, although the difference was not statistically significant. These findings suggest that decreased expression of immunoreactive 14-3-3sigma may be a predictor of poor prognosis in patients with UPSC.  (+info)

Solid and cystic papillary neoplasm of the pancreas in a 18-year-old female: a case report. (64/83)

 (+info)